Illumavista Nets $370K from NIH to Develop TF-Focused SNAP Array Platform | GenomeWeb

By Justin Petrone

The National Institutes of Health recently awarded Illumavista Biosciences $370,000 to develop a microarray platform for studying transcription factor binding.

Specifically, the Madison, Wis.-based firm received $150,000 to support a project entitled, "High-throughput method to assess SNP functionality in prostate cancer," and $268,168 to fund a second project, "Screening of FoxA1-ER-DNA disruptors for development of breast cancer therapeutic."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.